Domain Therapeutics’s technology pipeline is based on genetically-encoded biosensor assays for profiling cell surface receptor signaling and activity.

All of our technologies are created with the same underlying goal:
To develop simple, sensitive and robust assays that are HTS compatible.

At the heart of Domain Therapeutics’s technology pipeline is the bioSensAll platform of sensors for the study of G protein-coupled receptors (GPCRs). A novel suite of biosensors aimed at profiling receptors outside the GPCR family is currently under development.

bioSensAll G alpha activation (GAPL) biosensor assay principle

Download PDF